Abstract
The development of photoactive and biocompatible nanomaterials is a current major challenge of materials science and nanotechnology, as they will contribute to promoting current and future biomedical applications. A growing strategy in this direction consists of using biologically inspired hybrid materials to maintain or even enhance the optical properties of chromophores and fluorophores in biological media. Within this area, porphyrinoids constitute the most important family of organic photosensitizers. The following extensive review will cover their incorporation into different kinds of photosensitizing biohybrid materials, as a fundamental research effort toward the management of light for biomedical use, including technologies such as photochemical internalization (PCI), photoimmunotherapy (PIT), and theranostic combinations of fluorescence imaging and photodynamic therapy (PDT) or photodynamic inactivation (PDI) of microorganisms.
| Original language | English |
|---|---|
| Pages (from-to) | 7369-7400 |
| Number of pages | 32 |
| Journal | Chemical Society Reviews |
| Volume | 47 |
| Issue number | 19 |
| DOIs | |
| Publication status | Published - 7 Oct 2018 |
| MoE publication type | A2 Review article, Literature review, Systematic review |
Funding
European Union’s Seventh Framework Program FP7-PEOPLE-2012-ITN under REA grant agreement no. GA 316975. This work was supported by the EU (CosmoPHOS-nano, FP7-NMP-2012-6, 310337-2), Spanish MINECO (CTQ2017-85393-P (TT), CTQ-2014-53673-P and CTQ-2017-89539-P (AdlE), PCIN-2017-042/ EuroNanoMed2017-191, TEMPEAT (TT)), and the Comunidad Autonoma de Madrid (FOTOCARBON, S2013/MIT-2841). IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (MINECO, Grant SEV-2016-0686). Eveline van de Winckel graduated from the University of Ghent (Belgium) as an MSc in Chemistry in 2013. Afterwards, she continued her postgraduate research in the field of photodynamic therapy at the Universidad Autónoma de Madrid (Spain), funded by a Marie Curie scholarship. After completing her PhD in 2017, Eveline’s current interests focus on the transfer of her expertise in light-induced therapies for cancer treatment into clinical research, holding a Clinical Research Associate position in the pharmaceutical industry and actively participating in the organization of Phase I to Phase III clinical trials in different oncological areas. The work carried out to write this review article has received funding from the People Program (Marie Curie Actions) of the The work carried out to write this review article has received funding from the People Program (Marie Curie Actions) of the European Union’s Seventh Framework Program FP7-PEOPLE-2012-ITN under REA grant agreement no. GA 316975. This work was supported by the EU (CosmoPHOS-nano, FP7-NMP-2012-6, 310337-2), Spanish MINECO (CTQ2017-85393-P (TT), CTQ-2014-53673-P and CTQ-2017-89539-P (AdlE), PCIN-2017-042/ EuroNanoMed2017-191, TEMPEAT (TT)), and the Comunidad Autonoma de Madrid (FOTOCARBON, S2013/MIT-2841). IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (MINECO, Grant SEV-2016-0686).